Accumulating evidence supports the concept that cancer stem cells (CSCs) are responsible for tumor initiation and maintenance. They are also considered as an attractive target for advanced cancer therapy. Using a sphere culture method that favors the growth of self-renewal cells, we have isolated sphere-forming cells (SFCs) from cervical cancer cell lines HeLa and SiHa. HeLa-SFCs were resistant to multiple chemotherapeutic drugs and were more tumorigenic, as evidenced by the growth of tumors following injection of immunodeficient mice with 1 × 10 4 cells, compared with 1 × 10 6 parental HeLa cells required to grow tumors of similar size in the same time frame. These cells showed an expression pattern of CD44 high/CD24 low that resembles the CSC surface biomarker of breast cancer. We further demonstrated that HeLa-SFCs expressed a higher level (6.9-fold) of the human papillomavirus oncogene E6, compared with that of parental HeLa cells. Gene silencing of E6 with a lentiviral-short-hairpin RNA (shRNA) profoundly inhibited HeLa-SFC sphere formation and cell growth. The inhibition of cell growth was even greater than that for sphere formation after E6 silence, suggesting that the loss of self-renewing ability may be more important. We then measured the expression of self-renewal genes, transformation growth factor-beta (TGF-Β) and leukemia-inhibitory factor (LIF), in shRNA-transduced HeLa-SFCs and found that expression of all three TGF-Β isoforms was significantly downregulated while LIF remained unchanged. Expression of the Ras gene (a downstream component of TGF-Β) was also markedly decreased, suggesting that the growth-inhibitory effect could be via the TGF-Β pathway. The above data indicate RNA interference-based therapy may offer a new approach for CSC-targeted cancer therapy. © 2011 Nature America, Inc. All rights reserved.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Gu, W., Yeo, E., McMillan, N., & Yu, C. (2011). Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability. Cancer Gene Therapy, 18(12), 897–905. https://doi.org/10.1038/cgt.2011.58